Latest News
In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.
A new BrightFocus-funded study of cognitively healthy 100-year-olds sheds light on genetic characteristics that protect the brain.
Increased eye inflammation with age may contribute to macular degeneration and present differently between sexes, suggests a new BrightFocus-funded study.
Another disease-modifying Alzheimer's therapy hits the market.
On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.
In This Issue:
- President’s Corner
- Exercise-Induced Hormone Could Treat Alzheimer’s Disease
- Researcher Spotlight: Ariel Gilad, PhD
- Tips for Managing Caregiver Stress
- Zoom In on Dementia & Alzheimer’s
- Help Fight Alzheimer’s Through a Will or Bequest
In response to overwhelming interest in its first six episodes, four additional episodes of Zoom In on Dementia & Alzheimer’s will walk participants through specific Alzheimer’s clinical trials and research studies.
BrightFocus Foundation hosted its inaugural Concert for Cures on Wednesday, June 26, at City Winery in Nashville.
A new BrightFocus-funded glaucoma vision research study suggests that Black and Asian people receive a critical glaucoma screening test less frequently than others, which could delay sight-saving treatment.
A new BrightFocus-funded study found that identifying disruptive sleep patterns may help identify people at risk of Alzheimer’s disease up to seven years prior to end of life.
